GlassScriptPhysician profile
Ismail A Bobat
NPI 1750310553
$58,350.47
in general payments reported to CMS, 2019-2025
19 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,212 · 2021: $1,006 · 2022: $198 · 2023: $4,202 · 2024: $21K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Honoraria: $5,800 · Food and Beverage: $3,723 · Travel and Lodging: $3,541 · Education: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,234.00 |
| Honoraria | $5,800.00 |
| Food and Beverage | $3,723.12 |
| Travel and Lodging | $3,541.48 |
| Education | $636.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48,931.08 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Verona Pharma, INC. | $6,232.21 | 2025 | Ohtuvayre |
| Ethicon INC. | $963.60 | 2021 | |
| Genzyme Corporation | $487.23 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $385.78 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.55 | 2022-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $285.15 | 2021-2025 | Nucala, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $230.47 | 2025 | Inspire |
| Grifols USA, LLC | $128.30 | 2022-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $72.06 | 2019 | |
| Insmed, INC. | $63.57 | 2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $53.54 | 2022-2024 | Yupelri |
| Electromed, INC. | $50.58 | 2023-2024 | Smartvest |
| Axsome Therapeutics, INC. | $29.88 | 2024-2025 | Sunosi |
| Pulmonx Corporation | $28.36 | 2022-2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.00 | 2025 | Mounjaro, Zepbound |
| Resmed Corp | $16.47 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $14.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.66 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ismail Bobat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.